|

SVF Cellular Composition, Secretome, and Responses in Knee Osteoarthritis

RECRUITINGSponsored by Yonsei University
Actively Recruiting
SponsorYonsei University
Started2026-11-01
Est. completion2028-09-30
Eligibility
Age40 Years – 75 Years
Healthy vol.Accepted

Summary

This prospective, single-center observational study will enroll 20 adults aged 40 to 75 years with Kellgren-Lawrence grade II or III knee osteoarthritis who have already been scheduled for an intra-articular injection of autologous adipose-derived stromal vascular fraction (SVF) as clinical care. The study does not assign treatment, use a control group, or randomize participants. After preparation of the therapeutic SVF, residual adipose tissue will be processed independently with a new disposable kit to obtain research-only SVF. No additional adipose tissue will be harvested for research, and research-only SVF will not be injected. Cellular composition and secretome characteristics of research-only SVF will be measured. Synovial fluid biomarkers will be assessed before injection and at 6 months using the same 12-analyte panel. Patient-reported outcomes and knee radiographs will also be compared between baseline and 6 months. CGBio provides research funding and research-only processing kits without involvement in study conduct, analysis, or publication decisions.

Eligibility

Age: 40 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Age 40-75 years at written consent; all sexes.
2. ACR-defined primary knee osteoarthritis; target-knee pain for at least 3 months.
3. Target-knee Kellgren-Lawrence grade II or III.
4. Baseline activity pain VAS at least 4/10.
5. Persistent symptoms despite conservative therapy; prior clinical decision for SVF injection.
6. Voluntary written informed consent. 7. Ability to comply with follow-up and assessments.

Exclusion Criteria:

1. Target-knee Kellgren-Lawrence grade I or IV.
2. Secondary arthritis (infectious, rheumatoid, gouty, reactive, or other causes).
3. Relevant joint disease affecting assessment: recurrent pseudogout, intra-articular fracture, hemochromatosis, Wilson disease, inherited connective-tissue disease, or other significant disease.
4. BMI ≥35 kg/m². 5. Prior total/partial target-knee arthroplasty.

6\. Target-knee surgery/arthroscopy within 6 months before screening. 7. Target-knee steroid/PRP injection within 3 months before screening. 8. Target-knee hyaluronic acid injection within 1 month before screening. 9. Target-knee cell therapy/SVF/other regenerative injection within 6 months before screening.

10\. Active systemic infection or local infection at donor site/target knee. 11. Severe cardiovascular/hepatic/renal or uncontrolled systemic disease increasing procedural risk.

12\. Active malignancy under treatment or investigator-determined unsuitable cancer history.

13\. Inability to undergo protocol knee radiographs. 14. Pregnancy/breastfeeding.

15\. Inadequate donor fat for safe liposuction. 16. Cognitive/psychiatric impairment or alcohol/drug dependence preventing understanding/cooperation.

Conditions2

ArthritisOsteoarthritis, Knee

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.